Importantly, trials of SGLT2 inhibitors, finerenone and semaglutide have demonstrated that these therapies not only reduced the incidence of renal outcomes, but also major adverse CV events compared with placebo in people with type 2 diabetes and CKD [132, 148, 149, 152, 154]. Here, SLC5A2 is linked to type 2 diabetes mellitus.